
RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00.
Shares of ADC Therapeutics are trading down 1.34% over the last 24 hours, at $7.71 per share.

RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00.
Shares of ADC Therapeutics are trading down 1.34% over the last 24 hours, at $7.71 per share.